Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 823481, 7 pages
http://dx.doi.org/10.1155/2015/823481
Review Article

The Role of Vaspin in the Development of Metabolic and Glucose Tolerance Disorders and Atherosclerosis

Department of Diabetology, Clinical Centre of Endocrinology, Medical University, 2 Zdrave Street, 1431 Sofia, Bulgaria

Received 4 March 2015; Accepted 30 March 2015

Academic Editor: Kosmas Paraskevas

Copyright © 2015 Rumyana Dimova and Tsvetalina Tankova. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J.-P. Després, A. Cartier, M. Côté, and B. J. Arsenault, “The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology,” Annals of Medicine, vol. 40, no. 7, pp. 514–523, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Fruhbeck, J. Gomez-Ambrosi, F. J. Muruzabal, and M. A. Burrell, “The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 280, no. 6, pp. 827–847, 2001. View at Google Scholar
  4. E. E. Kershaw and J. S. Flier, “Adipose tissue as an endocrine organ,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2548–2556, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. B. L. Wajchenberg, “Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome,” Endocrine Reviews, vol. 21, no. 6, pp. 697–738, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Hida, J. Wada, J. Eguchi et al., “Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 30, pp. 10610–10615, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Wada, “Vaspin: a novel serpin with insulin-sensitizing effects,” Expert Opinion on Investigational Drugs, vol. 17, no. 3, pp. 327–333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. Q. Li, R. Chen, J. Moriya et al., “A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity,” Journal of International Medical Research, vol. 36, no. 4, pp. 625–629, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. P. G. W. Gettins, “Serpin structure, mechanism, and function,” Chemical Reviews, vol. 102, no. 12, pp. 4751–4804, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Nakatsuka, J. Wada, I. Iseda et al., “Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex,” Diabetes, vol. 61, no. 11, pp. 2823–2832, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Nakatsuka, J. Wada, I. Iseda et al., “Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex,” Circulation Research, vol. 112, no. 5, pp. 771–780, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Liu, Y. Dong, T. Wang et al., “Vaspin inhibited proinflammatory cytokine induced activation of nuclear factor-kappa B and its downstream molecules in human endothelial EA.hy926 cells,” Diabetes Research and Clinical Practice, vol. 103, no. 3, pp. 482–488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Blüher, “Vaspin in obesity and diabetes: pathophysiological and clinical significance,” Endocrine, vol. 41, no. 2, pp. 176–182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. T. Heiker, N. Klöting, P. Kovacs et al., “Vaspin inhibits kallikrein 7 by serpin mechanism,” Cellular and Molecular Life Sciences, vol. 70, no. 14, pp. 2569–2583, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. T. Heiker, “Vaspin (serpinA12) in obesity, insulin resistance, and inflammation,” Journal of Peptide Science, vol. 20, no. 5, pp. 299–306, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. B.-S. Youn, N. Klöting, J. Kratzsch et al., “Serum vaspin concentrations in human obesity and type 2 diabetes,” Diabetes, vol. 57, no. 2, pp. 372–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Teshigawara, J. Wada, K. Hida et al., “Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population,” Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 7, pp. E1202–E1207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Hida, P. Poulsen, S. Teshigawara et al., “Impact of circulating vaspin levels on metabolic variables in elderly twins,” Diabetologia, vol. 55, no. 2, pp. 530–532, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Breitfeld, A. Tönjes, Y. Böttcher et al., “Genetic variation in the vaspin gene affects circulating serum vaspin concentrations,” International Journal of Obesity, vol. 37, no. 6, pp. 861–866, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Jeong, B.-S. Youn, D. W. Kim et al., “Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 4, pp. 1869–1875, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Lago, C. Dieguez, J. Gómez-Reino, and O. Gualillo, “The emerging role of adipokines as mediators of inflammation and immune responses,” Cytokine & Growth Factor Reviews, vol. 18, no. 3-4, pp. 313–325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Klöting, J. Berndt, S. Kralisch et al., “Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes,” Biochemical and Biophysical Research Communications, vol. 339, no. 1, pp. 430–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. H. M. Chang, H. J. Lee, H. S. Park et al., “Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance,” Obesity, vol. 18, no. 11, pp. 2105–2110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. N. Fain, B. Buehrer, S. W. Bahouth, D. S. Tichansky, and A. K. Madan, “Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue,” Metabolism: Clinical and Experimental, vol. 57, no. 7, pp. 1005–1015, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. C. R. González, J. E. Caminos, M. J. Vázquez et al., “Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue,” Journal of Physiology, vol. 587, no. 14, pp. 3741–3750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. S. Edgerton, K. M. S. Johnson, and A. D. Cherrington, “Current strategies for the inhibition of hepatic glucose production in type 2 diabetes,” Frontiers in Bioscience, vol. 14, no. 3, pp. 1169–1181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. N. E. Gulcelik, J. Karakaya, A. Gedik, A. Usman, and A. Gurlek, “Serum vaspin levels in type 2 diabetic women in relation to microvascular complications,” European Journal of Endocrinology, vol. 160, no. 1, pp. 65–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. K. Tan, D. Heutling, J. Chen et al., “Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance,” Diabetes, vol. 57, no. 6, pp. 1501–1507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Handisurya, M. Riedl, G. Vila et al., “Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss,” Obesity Surgery, vol. 20, no. 2, pp. 198–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. H. M. Chang, H. S. Park, C.-Y. Park, Y. S. Song, and Y. J. Jang, “Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects,” Metabolism: Clinical and Experimental, vol. 59, no. 9, pp. 1276–1281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Suleymanoglu, E. Tascilar, O. Pirgon, S. Tapan, C. Meral, and A. Abaci, “Vaspin and its correlation with insulin sensitivity indices in obese children,” Diabetes Research and Clinical Practice, vol. 84, no. 3, pp. 325–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. K. Lee, Y. Jekal, J.-A. Im et al., “Reduced serum vaspin concentrations in obese children following short-term intensive lifestyle modification,” Clinica Chimica Acta, vol. 411, no. 5-6, pp. 381–385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Han, J. Cho, C. Ha, and H. Kang, “Serum vaspin levels and its relation to body fat and fitness,” The Journal of Exercise Nutrition and Biochemistry, vol. 17, no. 3, pp. 81–86, 2013. View at Publisher · View at Google Scholar
  34. S. H. Choi, S. H. Kwak, Y. Lee et al., “Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women,” Clinical Endocrinology, vol. 75, no. 5, pp. 628–635, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Esteghamati, S. Noshad, M. Mousavizadeh, A. Zandieh, and M. Nakhjavani, “Association of vaspin with metabolic syndrome: the pivotal role of insulin resistance,” Diabetes and Metabolism Journal, vol. 38, no. 3, pp. 242–243, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. Kim, T. N. Kim, and J. C. Won, “Association between serum vaspin level and metabolic syndrome in healthy korean subjects,” Metabolic Syndrome and Related Disorders, vol. 11, no. 6, pp. 385–391, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Yan, L. Li, H. Wang et al., “Correlation between adipocytokines levels and metabolic syndrome in type 2 diabetes mellitus,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 34, no. 2, pp. 275–278, 2014. View at Google Scholar
  38. J. Seeger, M. Ziegelmeier, A. Bachmann et al., “Serum levels of the adipokine vaspin in relation to metabolic and renal parameters,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 1, pp. 247–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Karbek, N. C. Bozkurt, O. Topaloglu et al., “Relationship of vaspin and apelin levels with insulin resistance and atherosclerosis in metabolic syndrome,” Minerva Endocrinologica, vol. 39, no. 2, pp. 99–105, 2014. View at Google Scholar
  40. C. von Loeffelholz, M. Möhlig, A. M. Arafat et al., “Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans,” European Journal of Endocrinology, vol. 162, no. 3, pp. 507–513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Auguet, Y. Quintero, D. Riesco et al., “New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women,” BMC Medical Genetics, vol. 12, article 60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Bashiri, A. Rahbaran, F. Gholami, S. Ahmadizad, S. Nikoukheslat, and A. Moradi, “The effect of acute exercise on serum vaspin level and its relation to insulin sensitivity in overweight elderly men,” Zahedan Journal of Research in Medical Sciences, vol. 16, no. 8, pp. 10–13, 2013. View at Google Scholar
  43. M. Blüher, A. Rudich, N. Klöting et al., “Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention,” Diabetes Care, vol. 35, no. 2, pp. 342–349, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. S. M. Kim, G. J. Cho, M. Yannakoulia et al., “Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations,” Metabolism: Clinical and Experimental, vol. 60, no. 9, pp. 1294–1299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Esaki, H. Adachi, Y. Hirai et al., “Serum vaspin levels are positively associated with carotid atherosclerosis in a general population,” Atherosclerosis, vol. 233, no. 1, pp. 248–252, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Thörne, F. Lönnqvist, J. Apelman, G. Hellers, and P. Arner, “A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding,” International Journal of Obesity, vol. 26, no. 2, pp. 93–99, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. A. H. Berg, T. P. Combs, and P. E. Scherer, “ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism,” Trends in Endocrinology & Metabolism, vol. 13, no. 2, pp. 84–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. R. S. Ahima and S. Y. Osei, “Adipokines in obesity,” Frontiers of Hormone Research, vol. 36, pp. 182–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Fantuzzi and T. Mazzone, “Adipose tissue and atherosclerosis: exploring the connection,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 5, pp. 996–1003, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. O. Leal Vde and D. Mafra, “Adipokines in obesity,” Clinica Chimica Acta, vol. 419, pp. 87–94, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. M. A. Kobat, A. Celik, M. Balin et al., “The investigation of serum vaspin level in atherosclerotic coronary artery disease,” Journal of Clinical Medicine Research, vol. 4, no. 2, pp. 110–113, 2012. View at Publisher · View at Google Scholar
  52. G. Aust, O. Richter, S. Rohm et al., “Vaspin serum concentrations in patients with carotid stenosis,” Atherosclerosis, vol. 204, no. 1, pp. 262–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. H. S. Cura, H. H. Özdemir, C. F. Demir, S. Bulut, N. Ilhan, and M. F. Inci, “Investigation of vaspin level in patients with acute ischemic stroke,” Journal of Stroke and Cerebrovascular Diseases, vol. 23, no. 3, pp. 453–456, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. N. P. E. Kadoglou, A. Gkontopoulos, A. Kapelouzou et al., “Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study,” Clinica Chimica Acta, vol. 412, no. 1-2, pp. 48–52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. S. I. Al-Azzam, K. H. Alzoubi, J. A. Abeeleh, N. M. Mhaidat, and M. Abu-Abeeleh, “Effect of statin therapy on vaspin levels in type 2 diabetic patients,” Clinical Pharmacology: Advances and Applications, vol. 5, no. 1, pp. 33–38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Kempf, B. Rose, T. Illig et al., “Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies,” Experimental and Clinical Endocrinology & Diabetes, vol. 118, no. 3, pp. 184–189, 2010. View at Publisher · View at Google Scholar
  57. Y. Ye, X.-H. Hou, X.-P. Pan, J.-X. Lu, and W.-P. Jia, “Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes,” Chinese Medical Journal, vol. 122, no. 21, pp. 2530–2533, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Li, L. Li, M. Yang et al., “Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity,” European Journal of Endocrinology, vol. 164, no. 6, pp. 905–910, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. R.-N. Feng, C. Wang, C.-H. Sun, F.-C. Guo, C. Zhao, and Y. Li, “Vaspin in newly and previously diagnosed Chinese type 2 diabetic females: a case-control study,” Asian Biomedicine, vol. 5, no. 4, pp. 525–529, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. W. Jian, W. Peng, S. Xiao et al., “Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study,” PLoS ONE, vol. 9, no. 4, Article ID e94763, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. H. B. Atya, Z. A. Hassan, A. I. Amin, and S. A. E. Ali, “Vaspin concentration in obesity, impaired glucose tolerance and type 2 diabetes in Egypt,” Advanced Research in Biological Sciences, vol. 1, no. 1, pp. 6–13, 2013. View at Google Scholar
  62. H. O. El-Mesallamy, D. H. Kassem, E. El-Demerdash, and A. I. Amin, “Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus,” Metabolism: Clinical and Experimental, vol. 60, no. 1, pp. 63–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. Z. Li, C. Ma, L. Li, X. Pan, and L. Chen, “Vaspin serum concentration in patients with type 2 diabetes and carotid plaque,” The Journal of International Medical Research, vol. 40, no. 5, pp. 1670–1676, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. R. N. Feng, Y. Li, C. Wang et al., “Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis,” Diabetes Research and Clinical Practice, vol. 106, no. 1, pp. 88–94, 2014. View at Publisher · View at Google Scholar
  65. M. Blüher, “Adipokines—removing road blocks to obesity and diabetes therapy,” Molecular Metabolism, vol. 3, no. 3, pp. 230–240, 2014. View at Publisher · View at Google Scholar · View at Scopus